Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination
Markus Hoffmann, Heike Hofmann-Winkler, Nadine Krüger, et al.
Cell Reports (2021) Vol. 36, Iss. 3, pp. 109415-109415
Open Access | Times Cited: 232

Showing 1-25 of 232 citing articles:

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization
Delphine Planas, David Veyer, Artem Baidaliuk, et al.
Nature (2021) Vol. 596, Iss. 7871, pp. 276-280
Open Access | Times Cited: 2013
The biological and clinical significance of emerging SARS-CoV-2 variants
Kaiming Tao, Philip L. Tzou, Janin Nouhin, et al.
Nature Reviews Genetics (2021) Vol. 22, Iss. 12, pp. 757-773
Open Access | Times Cited: 976
Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review
Thibault Fiolet, Yousra Kherabi, Conor-James MacDonald, et al.
Clinical Microbiology and Infection (2021) Vol. 28, Iss. 2, pp. 202-221
Open Access | Times Cited: 820
SARS-CoV-2 Spike Mutations, L452R, T478K, E484Q and P681R, in the Second Wave of COVID-19 in Maharashtra, India
Sarah Cherian, Varsha Potdar, Santosh Jadhav, et al.
Microorganisms (2021) Vol. 9, Iss. 7, pp. 1542-1542
Open Access | Times Cited: 628
Tackling COVID-19 with neutralizing monoclonal antibodies
Davide Corti, Lisa A. Purcell, Gyorgy Snell, et al.
Cell (2021) Vol. 184, Iss. 12, pp. 3086-3108
Open Access | Times Cited: 369
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Obbina Abani, Ali Abbas, Fatima Abbas, et al.
The Lancet (2022) Vol. 399, Iss. 10325, pp. 665-676
Open Access | Times Cited: 354
SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies
MacGregor Cox, Thomas P. Peacock, William T. Harvey, et al.
Nature Reviews Microbiology (2022) Vol. 21, Iss. 2, pp. 112-124
Open Access | Times Cited: 261
Impact of the Delta variant on vaccine efficacy and response strategies
Lianlian Bian, Qiushuang Gao, Fan Gao, et al.
Expert Review of Vaccines (2021) Vol. 20, Iss. 10, pp. 1201-1209
Open Access | Times Cited: 215
Monoclonal antibody therapies against SARS-CoV-2
Daniele Focosi, Scott A. McConnell, Arturo Casadevall, et al.
The Lancet Infectious Diseases (2022) Vol. 22, Iss. 11, pp. e311-e326
Open Access | Times Cited: 204
Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection
Yu‐Chyi Hwang, Ruei‐Min Lu, Shih-Chieh Su, et al.
Journal of Biomedical Science (2022) Vol. 29, Iss. 1
Open Access | Times Cited: 194
Immune Evasion of SARS-CoV-2 Emerging Variants: What Have We Learnt So Far?
Ivana Lazarević, Vera Pravica, Danijela Miljanovic, et al.
Viruses (2021) Vol. 13, Iss. 7, pp. 1192-1192
Open Access | Times Cited: 183
Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization
Dennis Lapuente, Jana Fuchs, Jonas Willar, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 183
SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19
Nina Kreuzberger, Caroline Hirsch, Khai Li Chai, et al.
Cochrane library (2021) Vol. 2021, Iss. 9
Open Access | Times Cited: 134
Emerging SARS-CoV-2 Variants: A Review of Its Mutations, Its Implications and Vaccine Efficacy
Sindhu Ramesh, Manoj Govindarajulu, Rachel S. Parise, et al.
Vaccines (2021) Vol. 9, Iss. 10, pp. 1195-1195
Open Access | Times Cited: 131
Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants
Rüdiger Groß, Michelle Zanoni, Alina Seidel, et al.
EBioMedicine (2021) Vol. 75, pp. 103761-103761
Open Access | Times Cited: 124
Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow Endemic SARS-CoV-2 Variants
Vladimir А. Gushchin, Inna V. Dolzhikova, А. М. Щетинин, et al.
Vaccines (2021) Vol. 9, Iss. 7, pp. 779-779
Open Access | Times Cited: 114
Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants
Cong Sun, Chu Xie, Guo‐Long Bu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 113
The Spike of Concern—The Novel Variants of SARS-CoV-2
Anna Winger, Thomas Caspari
Viruses (2021) Vol. 13, Iss. 6, pp. 1002-1002
Open Access | Times Cited: 110
Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity
Hylemariam Mihiretie Mengist, Arnaud John Kombe Kombe, Daniel Mekonnen, et al.
Seminars in Immunology (2021) Vol. 55, pp. 101533-101533
Open Access | Times Cited: 105
Reinfection in patients with COVID-19: a systematic review
Xiangying Ren, Jie Zhou, Jing Guo, et al.
Global Health Research and Policy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 90
SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies
S. Momsen Reincke, Meng Yuan, Hans‐Christian Kornau, et al.
Science (2022) Vol. 375, Iss. 6582, pp. 782-787
Open Access | Times Cited: 80
Development of therapeutic antibodies for the treatment of diseases
Zeng Wang, Guoqing Wang, Huaqing Lu, et al.
Molecular Biomedicine (2022) Vol. 3, Iss. 1
Open Access | Times Cited: 75
SARS-CoV-2 Variants Increase Kinetic Stability of Open Spike Conformations as an Evolutionary Strategy
Ziwei Yang, Yang Han, Shilei Ding, et al.
mBio (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 70
SARS-CoV-2 viral clearance and evolution varies by type and severity of immunodeficiency
Yijia Li, Manish C. Choudhary, James Regan, et al.
Science Translational Medicine (2024) Vol. 16, Iss. 731
Open Access | Times Cited: 48
The global epidemic of SARS‐CoV‐2 variants and their mutational immune escape
Dandan Tian, Yanhong Sun, Jianming Zhou, et al.
Journal of Medical Virology (2021) Vol. 94, Iss. 3, pp. 847-857
Open Access | Times Cited: 100
Page 1 - Next Page

Scroll to top